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Drug discovery today requires the focused use of laboratory
automation and other resources in combinatorial chemistry and
high-throughput screening (HTS). The ultimate value of both
combinatorial chemistry and HTS technologies and the lasting
impact they will have on the drug discovery process is a chapter that
remains to be written. Central to their success and impact is how
well they are integrated with each other and with the rest of the
drug discovery processes—informatics is key to this success. This
presentation focuses on informatics and the integration of the
disciplines of combinatorial chemistry and HTS in modern drug
discovery. Examples from experiences at Neurogen from the last
￿ ve years are described.
Introduction
Neurogen Corporation is a pharmaceutical company
focusing on central nervous system (CNS) disorders.
Several years ago, we began to develop methodology,
now named ` AIDD
SM’ for ` Accelerated Intelligent Drug
Discovery’ , with the aim of streamlining and optimizing:
. the generation of lead series,
. the exploration and characterization of lead series,
. the optimization of leads, and
. the optimization of clinical development candidates.
AIDD
SM accomplishes this through tight integration (via
intranet deployed informatics) of combinatorial chemis-
try, high-throughput pharmacology and computational
chemistry. AIDD
SM itself is tightly integrated with the
drug discovery e¶ ort and especially with medicinal
chemistry itself.
The focus of AIDD
SM is the ability to greatly enhance the
drug discovery cycle of synthesis, data generation, data
analysis and modelling, and to prioritize both synthesis
and screeningÐ thus completing the cycleÐ on thousands
of compounds every two weeks (® gure 1). Additionally,
this is accomplished with the following.
. Very small sta¶ resources (20± 25 full-time employ-
ees).
. Ability to synthesize 400,000 samples per year (as
either mixtures or individual samples) with puri® -
cation and quality assessment.
. Biological data generation of 300000 samples per
month.
. Cycle time of two weeks
. Targeted eµ ciency gains through computational
chemistry and data-mining of 10 £ to well over
50£ over random.
. Ability to prosecute 13± 15 programs simultaneously
in the above manner.
Virtual library
The AIDD
SM virtual library is managed by Neurogen’ s
ISLANDS
SM technology and is a representation of all
compounds that can be made from the existing reactive
fragment database and synthesis protocol database. Thus
this virtual library is a very speci® c and dynamic set of
compounds that can easily be millions or billions of
molecules in size. The ISLANDS
SM technology managing
the virtual library is key to AIDD
SM virtual screening
processes as well as to work¯ ow operations. The IS-
LANDS
SM software makes it possible to de® ne and
register 50000 compounds from the virtual library easily
and quickly (in 10 minutes). After de® nition and regis-
tration, not only do the compounds exist electronically in
databases for use in AIDD
SM but also ISLANDS
SM has
generated all the information required in the synthesis
itself. The reagents required, the synthesis, reaction
workup, and quality control protocols to be used by the
synthesis robotics, and all tracking information (sample
number, plate number, well locations) have been auto-
matically generated and speci® ed with no further input
from the user required.
Virtual screening
A key concept of AIDD
SM is the e¶ ective prioritization of
both synthesis and screening resources through virtual
screening. Proprietary, unattended and continuous mol-
ecular modelling and data-mining strategies termed ` On-
Line Continuous Modelling’ (OLCM) provide models
for virtual screening of both the virtual library and the
archive of actual compounds. These models work in
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Figure 1. AIDD
SM drug discovery cycle.
169concert with ISLANDS
SM for virtual screening of the
virtual library (® gure 2).
On-line continuous modelling
From the inception of our work on AIDD
SM, we planned
to perform computational chemistry modelling with a
novel portfolio approach. A portfolio of modelling stra-
tegies could be expected to provide useful models in a
variety of cases when no one strategy could be expected
to perform well in every situation. Compare this to a
stock portfolio where the expectation is that the portfolio
will increase in value with time even though this cannot
be expected of any one particular stock. The AIDD
SM
portfolio of OLCM strategies includes a variety of chemi-
cal descriptor types and a variety of modeling methods.
Fuzzy methods and machine methods have been very
e¶ ective. Both arti® cial neural networks and recursive
partitioning methodologies are also used routinely in
AIDD
SM OLCM studies.
A core principle of AIDD
SM and OLCM is the predic-
tion, prioritization and targeting of populations of com-
pounds instead of individual compounds. This makes it
possible to routinely achieve signi® cant bene® ts, by
increasing the probability of activity in each two-week
cycle. Eµ ciency gains or targeting enhancements seen in
AIDD
SM from this approach are routinely 10£ to more
than 50£ increased.
Results
AIDD
SM has been applied to over 15 diverse programs at
Neurogen: in each program AIDD
SM resulted in novel
leads that were readily optimized to signi® cant levels of
activity (® gure 3).
Neurogen has been applying AIDD
SM technology to the
optimization of drug-like properties within projects to-
ward the generation of development candidates. These
e¶ orts have resulted in more eµ cient optimization of
candidate ADME and PK properties such as metabolic
half-life, cytochrome P450 activity, and others.
Summary
An overview of the AIDD
SM Drug Discovery System at
Neurogen has been given. Speci® c examples from active
project areas were presented. The importance of integra-
tion of disciplines and of pragmatism in balancing the
individual components of drug discovery was stressed.
Figure 2. The AIDD
SM process. Figure 3. AIDD
SM scorecard.
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